COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0
|
作者：
Miller, B. [1 ]
Russel-Szymczyk, M. [2 ]
Jensen, I. S. [3 ]
Shah, A. [1 ]
Alexopoulos, S. T. [4 ]
Herbert, A. [4 ]
McLean, T. [4 ]
Tundia, N. [5 ]
机构：
[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA
[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England
[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE658
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [1] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [2] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [3] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [4] Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
    Bhan, Virender
    Clift, Fraser
    Baharnoori, Moogeh
    Thomas, Kimberly
    Patel, Barkha P.
    Blanchette, Francois
    Adlard, Nicholas
    Vudumula, Umakanth
    Gudala, Kapil
    Dutta, Nikkita
    Grima, Daniel
    Mouallif, Soukaina
    Farhane, Fatine
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
  • [5] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Michels, Renee Else
    de Fransesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
  • [6] Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria De Francesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2020, 18 : 141 - 141
  • [7] Cladribine is a safe and effective treatment for highly active relapsing-remitting multiple sclerosis
    Suslak, T.
    Macdougall, N.
    Murray, L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 269 - 269
  • [8] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [9] Effectiveness of cladribine tablets in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
    Habek, M.
    Brecl, G. Jakob
    Rajda, C.
    Adamec, I.
    Barun, B.
    Rok, A.
    Ledinek, A. Horvat
    Rot, U.
    Jazbec, S. Sega
    Gabelic, T.
    Klivenyi, P.
    Skoric, M. Krbot
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 894 - 894
  • [10] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
12345